Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth

Weidong Peng,Haojie Zhang,Mingwei Yin,Dejie Kong,Liping Kang,Xinkun Teng,Jingjing Wang,Zhimin Chu,Yating Sun,Pengpeng Long,Chengying Cui,Bin Lyu,Jinzhi Zhang,Han Xiao,Mingqing Wu,Yongqiang Wang,Yang Li

DOI: https://doi.org/10.1038/s41389-024-00529-y

2024-07-27

Oncogenesis

Abstract:Bladder cancer is characterized by aberrant activation of the phosphatidylinositol-3-OH kinase (PI3K) signaling, underscoring the significance of directing therapeutic efforts toward the PI3K pathway as a promising strategy. In this study, we discovered that PI3K serves as a potent therapeutic target for bladder cancer through a high-throughput screening of inhibitory molecules. The PI3K inhibitor demonstrated a robust anti-tumor efficacy, validated both in vitro and in vivo settings. Nevertheless, the feedback activation of JAK1-STAT3 signaling reinstated cell and organoid survival, leading to resistance against the PI3K inhibitor. Mechanistically, the PI3K inhibitor suppresses PTPN11 expression, a negative regulator of the JAK-STAT pathway, thereby activating STAT3. Conversely, restoration of PTPN11 enhances the sensitivity of cancer cells to the PI3K inhibitor. Simultaneous inhibition of both PI3K and STAT3 with small-molecule inhibitors resulted in sustained tumor regression in patient-derived bladder cancer xenografts. These findings advocate for a combinational therapeutic approach targeting both PI3K and STAT3 pathways to achieve enduring cancer eradication in vitro and in vivo, underscoring their promising therapeutic efficacy for treating bladder cancer.